

## MT2025-14: A Phase 1a/1b Study of GTB-5550, a Camelid Nanobody TriSpecific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- confirmed cancer that can be measured on scans - fully active, able to care for yourself - have recovered from side effects of any prior cancer treatments - have adequate blood counts, kidney, liver, heart, and lung function based on recent lab tests - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Inclusion criteria

---

**Exclusion Criteria:**

- recent cancer treatment (within 2 weeks) - have had a prior organ transplant - are pregnant or breastfeeding - another active or recent cancer - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Exclusion criteria

### Conditions & Interventions

**Interventions:**

Drug: GTB-5550

**Conditions:**

Cancer

**Keywords:**

Clinics and Surgery Center (CSC), solid tumor cancer

### More Information

**Description:** This study will test GTB-5550, a B7H3-targeted natural killer (NK) cell engager, for the treatment of select solid tumor cancers. The study will determine the optimal dose level and evaluate preliminary safety and efficacy.

**Study Contact:** Nicholas Zorko - [zorko004@umn.edu](mailto:zorko004@umn.edu)

**Principal Investigator:** Nicholas Zorko

**Phase:** PHASE1

**IRB Number:** STUDY00027558

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.